Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to -$3.6 million.

  • Innate Pharma's Non-Current Deffered Revenue rose 5149.4% to -$3.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$3.6 million, marking a year-over-year increase of 5149.4%. This contributed to the annual value of $3.1 million for FY2024, which is 3879.12% down from last year.
  • Per Innate Pharma's latest filing, its Non-Current Deffered Revenue stood at -$3.6 million for Q2 2025, which was up 5149.4% from $3.0 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Non-Current Deffered Revenue registered a high of $29.1 million during Q4 2021, and its lowest value of -$45.8 million during Q2 2021.
  • In the last 5 years, Innate Pharma's Non-Current Deffered Revenue had a median value of -$3.6 million in 2025 and averaged -$4.7 million.
  • The largest annual percentage gain for Innate Pharma's Non-Current Deffered Revenue in the last 5 years was 5943.53% (2022), contrasted with its biggest fall of 7220.19% (2022).
  • Quarter analysis of 5 years shows Innate Pharma's Non-Current Deffered Revenue stood at $29.1 million in 2021, then crashed by 72.2% to $8.1 million in 2022, then tumbled by 38.52% to $5.0 million in 2023, then plummeted by 39.24% to $3.0 million in 2024, then tumbled by 219.65% to -$3.6 million in 2025.
  • Its Non-Current Deffered Revenue was -$3.6 million in Q2 2025, compared to $3.0 million in Q4 2024 and -$7.4 million in Q2 2024.